Streetbeat News

Products Services

BIGC

BigCommerce (NASDAQ:BIGC) has announced a strategic partnership with Marketplacer to launch the BigCommerce Marketplacer Connector, enabling customers to transform their online stores into multi-vendor marketplaces. This connector, developed by Web Force 5, allows for near-real-time syncing of seller data, cross-border scalability, low coding requirements, and rapid data exchange. The DOM, Australia's leading design outlet, has successfully integrated this solution to enhance its marketplace functionalities and improve customer experience. The partnership aims to help retailers increase sales, maximize revenue, and provide seamless shopping experiences.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:02 pm

ACN

Accenture (NYSE:ACN) has invested in QuantHealth, an AI-powered clinical trial design company, through Accenture Ventures. QuantHealth's platform uses AI to simulate clinical trials, aiming to reduce costs and increase efficiency in drug development. The technology is based on a dataset of 350 million patients and can predict trial outcomes, optimize trial designs, and potentially lower the risk of trial failures. While financial terms were not disclosed, the investment is part of Accenture Ventures' Project Spotlight, which supports disruptive enterprise technologies.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:01 pm

ALHC

Alignment Healthcare reported a 44% increase in its Alignment Health Plan membership, reaching 155,500 members as of January 1. This significant growth in membership could indicate a positive trend for the company's business and potential revenue increases.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:01 pm

GOOG

GOOGL

LLY

NVS

Isomorphic Labs, an Alphabet Inc spin-off, has partnered with Eli Lilly and Novartis AG for AI-driven drug discovery. The deals are valued at around $3 billion, with Isomorphic receiving $45 million upfront from Eli Lilly and potentially $1.7 billion in milestones, and $37.5 million upfront from Novartis with up to $1.2 billion in incentives. Isomorphic uses DeepMind's AlphaFold 2 AI for predicting protein structures, aiding in drug design. Despite a £2.4 million loss in 2021, Isomorphic is expanding, including a new Swiss office. Google Cloud also launched AI tools for healthcare data consolidation.

Portfolio Pulse from Anusuya Lahiri

January 08, 2024 | 12:58 pm

ENVX

Enovix and Group14 have announced a collaboration to develop and enhance the performance and efficiency of lithium-ion silicon batteries, aligning with their dedication to innovation, renewable energy, and customer satisfaction.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 12:55 pm

AVXL

Anavex Life Sciences has been granted U.S. Patent No. 11,839,600 for Blarcamesine (ANAVEX2-73), a treatment for neurodevelopmental disorders. The patent was issued by the United States Patent and Trademark Office (USPTO) for patent application number 17/890,083.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 12:51 pm

MRNA

Moderna provided updates at the J.P. Morgan Healthcare Conference, projecting 2023 product sales of around $6.7B. The company's U.S. COVID-19 market share has risen to 48% in 2023 from 37% in 2022. Moderna reaffirmed its 2024 sales forecast of $4B, with a return to sales growth expected in 2025 and a break-even point anticipated in 2026 due to new product launches and disciplined investment.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 12:46 pm

ARQT

Arcutis Canada has announced that Health Canada has accepted a supplement to a New Drug Submission for Roflumilast Foam 0.3% intended for the treatment of Seborrheic Dermatitis in individuals aged 9 years and older.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 12:44 pm

ZVRA

Zevra has announced that the FDA has accepted the resubmission of its New Drug Application (NDA) for Arimoclomol, a proposed treatment for Niemann-Pick Disease Type C. The FDA has set a Prescription Drug User Fee Act (PDUFA) action date for June 21, 2024, and plans to discuss the resubmission in an advisory committee.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 12:43 pm

BABA

BIDU

NVDA

TCEHY

Nvidia Corp (NVDA) faces challenges in the Chinese market due to U.S. regulations barring high-performance AI chip sales. Major Chinese cloud companies like Alibaba (BABA) and Tencent (TCEHY) plan to reduce Nvidia chip orders, turning to local alternatives and in-house developments. Baidu (BIDU) and ByteDance are also shifting towards domestic producers like Huawei. Despite this, Nvidia sold over $1 billion of modified chips in China in 2023 and is developing new AI chips like the H20 for the Chinese market, set for production in Q2 2024. Nvidia's stock saw a slight increase on Monday.

Portfolio Pulse from Anusuya Lahiri

January 08, 2024 | 12:40 pm